{"protocolSection":{"identificationModule":{"nctId":"NCT01194453","orgStudyIdInfo":{"id":"HANSOH20090601"},"organization":{"fullName":"Sun Yat-sen University","class":"OTHER"},"briefTitle":"Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer","officialTitle":"A Phase 2,Open-label Study of First Line Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced and Metastatic Non Small Cell Lung Cancer and Biomarker Study","acronym":"AP/GP"},"statusModule":{"statusVerifiedDate":"2016-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2009-11"},"primaryCompletionDateStruct":{"date":"2010-09","type":"ACTUAL"},"completionDateStruct":{"date":"2012-08","type":"ACTUAL"},"studyFirstSubmitDate":"2010-08-25","studyFirstSubmitQcDate":"2010-09-01","studyFirstPostDateStruct":{"date":"2010-09-03","type":"ESTIMATED"},"resultsFirstSubmitDate":"2016-05-10","resultsFirstSubmitQcDate":"2016-05-10","resultsFirstPostDateStruct":{"date":"2016-06-16","type":"ESTIMATED"},"lastUpdateSubmitDate":"2016-05-10","lastUpdatePostDateStruct":{"date":"2016-06-16","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Li Zhang","investigatorTitle":"Professor","investigatorAffiliation":"Sun Yat-sen University"},"leadSponsor":{"name":"Sun Yat-sen University","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"A phase III trial has demonstrated that in advanced non-small cell lung cancer (NSCLC) cisplatin/ pemetrexed provides similar efficacy with better tolerability and more convenient administration than cisplatin/gemcitabine. Moreover,this trial showed survival differences based on histologic type. The investigators want to research some biomarkers that can predict clinical outcomes."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer","Efficacy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":288,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Group A","type":"EXPERIMENTAL","interventionNames":["Drug: cisplatin, dexamethasone,vitamin B12, folic acid"]},{"label":"Group B","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: cisplatin, gemcitabine"]}],"interventions":[{"type":"DRUG","name":"cisplatin, dexamethasone,vitamin B12, folic acid","description":"Patients received cisplatin 75mg/m2 plus pemetrexed 500 mg/m2 on day 1.Chemotherapy was repeated every 3 weeks for a maximum of six cycles.Patients received dexamethasone prophylaxis of 3.75mg orally twice per day on the day before, the day of, and the day after each day-1 treatment. patients received oral folic acid (1,000ug)daily and a vitamin B12 injection (1,000 ug) every 9 weeks, beginning 1 to 2 weeks before the first dose and continuing until 3 weeks after the last dose of study treatment","armGroupLabels":["Group A"]},{"type":"DRUG","name":"cisplatin, gemcitabine","description":"cisplatin 75mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8","armGroupLabels":["Group B"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression Free Survival (PFS)","timeFrame":"36months"}],"secondaryOutcomes":[{"measure":"Response Rate","timeFrame":"6 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Chemotherapy-naive patients with histologically or cytologically confirmed adenocarcinoma and large-cell carcinoma, classified as stage IIIB not amenable to curative treatment or stage IV\n2. With at least one unidimensionally measurable lesion according to the Response Evaluation Criteria in Solid Tumors;\n3. with an Eastern CooperativeOncology Group performance status of 0 or 1,\n4. At least 18 years of age\n5. adequate bone marrow reserve and organ function including calculated creatinine clearance 45 mL/min based on the standard Cockcroft and Gault formula.\n6. Prior radiation therapy was permitted if it was completed at least 4 weeks before study treatment\n7. patients had fully recovered from its acute effects.\n\nExclusion Criteria:\n\n1. peripheral neuropathy \\> National Cancer Institute Common Toxicity Criteria grade 1\n2. progressive brain metastases,\n3. uncontrolled third-space fluid retention before study entry.\n4. Patients unable to interrupt aspirin and other nonsteroidal anti-inflammatory drugs or if they were unable or unwilling to take folic acid, vitamin B12, or corticosteroids.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Li Zhang, MD","affiliation":"Cancer Center of Sun Yat-Sen University (CCSU)","role":"STUDY_CHAIR"}],"locations":[{"facility":"Cancer Center of Sun Yat-Sen University (CCSU)","city":"Guangzhou","state":"Guangdong","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}}]},"referencesModule":{"references":[{"pmid":"23075681","type":"DERIVED","citation":"Huang Y, Liu Y, Zhou J, Xu N, Li B, Wu G, Fang J, Li K, Liu X, Liu W, Lu Y, Wang M, Liu W, Liang H, Zhang Y, Huang C, Wang S, Wang Y, Yu S, Chang J, Wang Z, Hu Z, Zhang L. [A randomized, controlled, multicenter clinical trial comparing pemetrexed/cisplatin and gemcitabine/cisplatin as first-line treatment for advanced nonsquamous non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi. 2012 Oct;15(10):576-82. doi: 10.3779/j.issn.1009-3419.2012.10.03. Chinese."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Group A","description":"cisplatin, dexamethasone,vitamin B12, folic acid: Patients received cisplatin 75mg/m2 plus pemetrexed 500 mg/m2 on day 1.Chemotherapy was repeated every 3 weeks for a maximum of six cycles.Patients received dexamethasone prophylaxis of 3.75mg orally twice per day on the day before, the day of, and the day after each day-1 treatment. patients received oral folic acid (1,000ug)daily and a vitamin B12 injection (1,000 ug) every 9 weeks, beginning 1 to 2 weeks before the first dose and continuing until 3 weeks after the last dose of study treatment"},{"id":"FG001","title":"Group B","description":"cisplatin, gemcitabine: cisplatin 75mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"144"},{"groupId":"FG001","numSubjects":"144"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"127"},{"groupId":"FG001","numSubjects":"127"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"17"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Group A","description":"cisplatin, dexamethasone,vitamin B12, folic acid: Patients received cisplatin 75mg/m2 plus pemetrexed 500 mg/m2 on day 1.Chemotherapy was repeated every 3 weeks for a maximum of six cycles.Patients received dexamethasone prophylaxis of 3.75mg orally twice per day on the day before, the day of, and the day after each day-1 treatment. patients received oral folic acid (1,000ug)daily and a vitamin B12 injection (1,000 ug) every 9 weeks, beginning 1 to 2 weeks before the first dose and continuing until 3 weeks after the last dose of study treatment"},{"id":"BG001","title":"Group B","description":"cisplatin, gemcitabine: cisplatin 75mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"144"},{"groupId":"BG001","value":"144"},{"groupId":"BG002","value":"288"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"129"},{"groupId":"BG001","value":"120"},{"groupId":"BG002","value":"249"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"39"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"60"},{"groupId":"BG001","value":"73"},{"groupId":"BG002","value":"133"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"84"},{"groupId":"BG001","value":"71"},{"groupId":"BG002","value":"155"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"China","categories":[{"measurements":[{"groupId":"BG000","value":"144"},{"groupId":"BG001","value":"144"},{"groupId":"BG002","value":"288"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival (PFS)","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"day","timeFrame":"36months","groups":[{"id":"OG000","title":"Group A","description":"cisplatin, dexamethasone,vitamin B12, folic acid: Patients received cisplatin 75mg/m2 plus pemetrexed 500 mg/m2 on day 1.Chemotherapy was repeated every 3 weeks for a maximum of six cycles.Patients received dexamethasone prophylaxis of 3.75mg orally twice per day on the day before, the day of, and the day after each day-1 treatment. patients received oral folic acid (1,000ug)daily and a vitamin B12 injection (1,000 ug) every 9 weeks, beginning 1 to 2 weeks before the first dose and continuing until 3 weeks after the last dose of study treatment"},{"id":"OG001","title":"Group B","description":"cisplatin, gemcitabine: cisplatin 75mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"144"},{"groupId":"OG001","value":"144"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"168","lowerLimit":"139","upperLimit":"183"},{"groupId":"OG001","value":"140","lowerLimit":"113","upperLimit":"164"}]}]}]},{"type":"SECONDARY","title":"Response Rate","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage","timeFrame":"6 weeks","groups":[{"id":"OG000","title":"Group A","description":"cisplatin, dexamethasone,vitamin B12, folic acid: Patients received cisplatin 75mg/m2 plus pemetrexed 500 mg/m2 on day 1.Chemotherapy was repeated every 3 weeks for a maximum of six cycles.Patients received dexamethasone prophylaxis of 3.75mg orally twice per day on the day before, the day of, and the day after each day-1 treatment. patients received oral folic acid (1,000ug)daily and a vitamin B12 injection (1,000 ug) every 9 weeks, beginning 1 to 2 weeks before the first dose and continuing until 3 weeks after the last dose of study treatment"},{"id":"OG001","title":"Group B","description":"cisplatin, gemcitabine: cisplatin 75mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"127"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.41"},{"groupId":"OG001","value":"14.17"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From the delivery of the study drug to 21 days post the last dose of study drug.","eventGroups":[{"id":"EG000","title":"Group A","description":"cisplatin, dexamethasone,vitamin B12, folic acid: Patients received cisplatin 75mg/m2 plus pemetrexed 500 mg/m2 on day 1.Chemotherapy was repeated every 3 weeks for a maximum of six cycles.Patients received dexamethasone prophylaxis of 3.75mg orally twice per day on the day before, the day of, and the day after each day-1 treatment. patients received oral folic acid (1,000ug)daily and a vitamin B12 injection (1,000 ug) every 9 weeks, beginning 1 to 2 weeks before the first dose and continuing until 3 weeks after the last dose of study treatment","seriousNumAffected":5,"seriousNumAtRisk":144,"otherNumAffected":131,"otherNumAtRisk":144},{"id":"EG001","title":"Group B","description":"cisplatin, gemcitabine: cisplatin 75mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8","seriousNumAffected":5,"seriousNumAtRisk":144,"otherNumAffected":140,"otherNumAtRisk":144}],"seriousEvents":[{"term":"Leading to Hospitalization","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Obstructive pneumonia","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":144},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":144}]},{"term":"Death","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":144},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":144}]},{"term":"Life threatening","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":144},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":144}]},{"term":"Delay hospitalization","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":144},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":144}]}],"otherEvents":[{"term":"leukopenia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":63,"numAffected":63,"numAtRisk":144},{"groupId":"EG001","numEvents":69,"numAffected":69,"numAtRisk":144}]},{"term":"neutropenia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":64,"numAffected":64,"numAtRisk":144},{"groupId":"EG001","numEvents":59,"numAffected":59,"numAtRisk":144}]},{"term":"anemia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":34,"numAtRisk":144},{"groupId":"EG001","numEvents":48,"numAffected":48,"numAtRisk":144}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Dr. Li Zhang","organization":"Sun Yat-sen University Cancer Center","email":"zhangli6@mail.sysu.edu.cn","phone":"87342288"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D002945","term":"Cisplatin"},{"id":"D003907","term":"Dexamethasone"},{"id":"D014805","term":"Vitamin B 12"},{"id":"D005492","term":"Folic Acid"},{"id":"D000093542","term":"Gemcitabine"}],"ancestors":[{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"},{"id":"D011246","term":"Pregnadienetriols"},{"id":"D011245","term":"Pregnadienes"},{"id":"D011278","term":"Pregnanes"},{"id":"D013256","term":"Steroids"},{"id":"D000072473","term":"Fused-Ring Compounds"},{"id":"D011083","term":"Polycyclic Compounds"},{"id":"D013259","term":"Steroids, Fluorinated"},{"id":"D045728","term":"Corrinoids"},{"id":"D045725","term":"Tetrapyrroles"},{"id":"D011758","term":"Pyrroles"},{"id":"D001393","term":"Azoles"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D006576","term":"Heterocyclic Compounds, 4 or More Rings"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D047028","term":"Macrocyclic Compounds"},{"id":"D011622","term":"Pterins"},{"id":"D011621","term":"Pteridines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D003841","term":"Deoxycytidine"},{"id":"D003562","term":"Cytidine"},{"id":"D011741","term":"Pyrimidine Nucleosides"},{"id":"D011743","term":"Pyrimidines"}]}},"hasResults":true}